Interestingly, SET has been reported to have a relevant role in EMT in pancreatic cancer via N-cadherin regulation. SET overexpression was found to activate signaling through Rac1/JNK/cJun, thereby inducing the transcriptional activation of N-cadherin expression. In fact, SET overexpression positively correlated with N-Cadherin levels. 4 These observations would indicate that the direct miR-199b-induced N-cadherin regulation would be indirectly reinforced by modulating SET.
Furthermore, the authors showed that miR-199b predicted poor outcome in their HCC cohort and reduced TGF-β1-induced Akt phosphorylation. In concordance, SET overexpression has been described to confer poor clinical outcome and correlate with p-Akt expression in HCC tumors. 5 SET is a potent endogenous inhibitor of the tumor suppressor protein phosphatase 2A (PP2A), and PP2A activation has been reported to suppress TGF-β1-induced EMT. 6 In addition, PP2A directly targets and dephosphorylates Akt, which has also been described in HCC. 7 In fact, SET targeting using an antagonist to this protein restored PP2A-mediated p-Akt downregulation and induced apoptosis of HCC cells. 5 Finally, Zhou et al. found that miR-199b inhibits both migration and invasion in HCC cells, and some evidence highlights the potential involvement of SET in these effects. First, SET has a role inducing Rac1-mediated migration. 8 Second, a recent work has described that matrix metalloproteinase-9 (MMP-9) deregulation through PP2A inhibition is a relevant event in HCC that contributes to the tumor invasion, 9 and the PP2A inhibitor SET has been reported to induce MMP-9 expression activity in breast and nonsmall cell lung cancer. 10, 11 Altogether, the work by Zhou et al. 12 suggest that miR-199b/N-cadherin deregulation is a relevant event that predicts poor outcome and contributes to EMT in HCC. However, forthcoming studies are warranted to confirm the wide range of evidence indicating that SET could also be having a key role in the miR-199b/N-cadherin interplay. 
